U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Methylphenidate

; .

Author Information and Affiliations

Last Update: January 2, 2023.

Continuing Education Activity

Methylphenidate is FDA-approved for treating attention deficit hyperactivity disorder (ADHD) in children and adults and as a second-line treatment for narcolepsy in adults. Children diagnosed with ADHD should be at least six years of age or older before being started on this medication. Off-label uses of methylphenidate include treatment for fatigue in patients with cancer, refractory depression in the geriatric population, apathy in Alzheimer's disease, and enhancing cognitive performance (e.g., memory). The efficacy of methylphenidate for its off-label uses varies from limited to moderate. This activity will highlight the mechanism of action, adverse event profile/toxicity, pharmacology, monitoring, relevant interactions, and street names of methylphenidate, pertinent for interprofessional team members should they encounter a patient who requires therapy with or has potentially misused this drug.

Objectives:

  • Review the mechanism of action of methylphenidate.
  • Identify the approved and off-label uses of methylphenidate.
  • Summarize the contraindications and adverse events associated with methylphenidate.
  • Describe interprofessional team strategies for improving care coordination and communication to properly use methylphenidate to improve patient outcomes in the varied scenarios where it can be effective.
Access free multiple choice questions on this topic.

Indications

Methylphenidate is FDA-approved for treating attention deficit hyperactivity disorder (ADHD) in children and adults and as a second-line treatment for narcolepsy in adults.[1][2] 

Children diagnosed with ADHD should be at least six years of age or older before being started on this medication. The treatment of both ADHD and narcolepsy have significantly better outcomes when used concurrently with nonpharmacologic therapies (i.e., social skills training in ADHD or sleep hygiene measures in narcolepsy). 

Off-label uses of methylphenidate include treatment for fatigue in patients with cancer, refractory depression in the geriatric population, apathy in Alzheimer disease, and enhancing cognitive performance (e.g., memory).[3][4][5][6][7][8] Since it can be abused as a cognitive enhancer, it is a federally controlled Schedule II substance. The efficacy of methylphenidate for its off-label uses varies from limited to moderate. Most of these relatively newer uses are still being studied and implemented into clinical practice.

Mechanism of Action

Methylphenidate blocks the reuptake of two neurotransmitters, norepinephrine (NE) and dopamine, in presynaptic neurons. More specifically, it inhibits the transporters of these neurotransmitters, increasing the concentration of dopamine and NE in the synaptic cleft.[9] This creates its classic stimulant effect within the central nervous system (CNS), mainly in the prefrontal cortex. It chemically derives from phenethylamine and benzylpiperazine. It undergoes metabolism by the liver to ritalinic acid through a process called de-esterification via carboxylesterase CES1A1. Compared to other medications (i.e., amphetamines) that are phenethylamine derivatives, methylphenidate appears to increase the firing rate of neurons.[10] It is also a weak agonist at the 5HT1A receptor, which is an additional mechanism that contributes to the increased levels of dopamine.[11] 

With the increase in dopamine levels, methylphenidate can provide neuroprotection in certain conditions like Parkinson disease, which involves loss of dopaminergic neurons and methamphetamine abuse.[12] This effect occurs not only through its direct inhibition of the dopamine transporter but also via indirect regulation of the vesicular monoamine transporter 2. The combined interactions methylphenidate has on both of these transporters reduce the amount of dopamine that accumulates within the cytoplasm in patients with these conditions, thereby preventing the formation of reactive oxygen species that would otherwise be dangerously toxic to the brain. 

Dependence

The therapeutic dosages for ADHD or narcolepsy that physicians prescribe are not harmful enough to activate the reward system within the CNS, known as the nucleus accumbens. However, excessively higher dosages taken by those who intentionally abuse the drug lead to an overexpression of deltaFosB, a transcriptional activator, in specific neurons within the striatum. This accumulation of deltaFosB in the nucleus accumbens activates a series of signaling cascades that further triggers the addiction.[13]

Pharmacokinetics

  • Absorption: Slow but extensive; relative bioavailability for extended-release tablets 105% in children and 101% in adults (verses immediate-release tablets); the absolute oral bioavailability for extended-release capsules in children was 22% and 5% for d-methylphenidate and l-methylphenidate, respectively. 
  • Time of peak plasma concentration: 1.9 hours for immediate-release tablets and 4.7 hours for extended-release tablets
  • Food effects: Increase total exposure and peak plasma concentration; reduce the time for peak plasma concentration for extended-release tablets.
  • Alcohol effect: 98% of the drug from extended-release 40 mg capsule dosage form was released in an alcohol concentration of 40% in an in-vitro study.
  • Distribution: Volume of distribution was 2.65 and 1.80 L/kg for d- methylphenidate and l- methylphenidate, respectively.
  • Plasma Protein Binding: 10% to 33%
  • Metabolism: It is primarily metabolized by de-esterification to ritalinic acid, which is pharmacologically inactive.
  • Excretion: A majority of the drug (78% to 97%) is excreted in the urine, while small amounts are excreted in feces.

Administration

For medical purposes, methylphenidate is mainly given orally or, less commonly, as a transdermal patch. Multiple oral formulations are available that categorize according to how quickly the drug is released: immediate (IR), extended (XR or ER), and sustained. Two of the more unique formulations of methylphenidate are its ER sphenoidal oral drug absorption system that has a bimodal release and the osmotic (controlled) release delivery system. There are chewable tablets (either IR or ER) for children and an IR solution. Doses should not exceed 72 mg, the maximum dose of the ER tablet. If using the transdermal patch, the patient must be aware of placing the patch on the opposite hip each time to achieve its full effect. Those who misuse methylphenidate for recreational purposes prefer to use the intravenous (IV) or the intranasal route. Assess the risk of abuse before prescribing methylphenidate in any form.

Available Dosage Forms and Strengths 

  • Attention deficit disorder (ADD) in adults and pediatric patients (6 years and older) and for narcolepsy
    • Chewable tablets: 2.5 mg, 5 mg, and 10 mg
    • Immediate-release tablets: 5 mg, 10 mg, and 20 mg
  • Attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients (6 years and older) and for narcolepsy
    • Immediate-release tablets: 5 mg, 10 mg, and 20 mg
    • Extended-release tablets: 10 mg, 20 mg, 18 mg, 27 mg, 36mg, 54 mg, and 72 mg
    • Extended-release tablets (24 hours): 18 mg, 27 mg, 36mg, and 54 mg
    • Extended-release capsules: 10 mg, 20 mg, 30 mg, and 40 mg
    • Extended-release capsules CD: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg
    • Solution: 5 mg/ 5 ml and 10 mg / 5 ml in 500 ml bottle
    • ADHD in adults and pediatric patients (6 years and older) as well as for narcolepsy
  • Attention deficit hyperactivity disorder (ADHD) in pediatric patients (age 6 to 17 years)
    • Orally disintegrating tablets: 8.6 mg, 13.7 mg, and 25.9 mg
    • Patch: 10 mg, 15 mg, 20 mg, and 30 mg nominal dose over 9 hours

 Specific Patients Population 

  • Patient with Hepatic Impairment: There is no dose adjustment guidance in the manufacturer label for patients with hepatic impairment.
  • Patient with Renal Impairment: There is no dose adjustment guidance in the manufacturer label for patients with renal impairment. However, most of the drug and its metabolites are excreted in the urine. 
  • Pregnant Women: It is considered as pregnancy category C medicine. Many researchers studied methylphenidate during pregnancy to treat ADHD and narcolepsy, However, data is conflicting so use the medication with caution.[14][15][16][17]
  • Breastfeeding Women: It is recommended to monitor and keep relative infant dose below 10% while using methylphenidate therapy in nursing mothers as the drug is present in breast milk.[18][19]
  • Pediatric Patients: There are multiple dosage forms and strengths available for pediatric patients ages ranging from 6 years to 17 years.
  • Geriatric Patients: There is no specific dose adjustment guidance available.

Adverse Effects

Insomnia and nervousness are the most commonly reported adverse effects in patients using methylphenidate.[20]

Growth retardation (decreased height, weight, and bone marrow density) is observed when taken long-term in children.[21]

Other frequent side effects mainly involve the CNS (dizziness, headache, tics, restlessness/akathisia), gastrointestinal (nausea/vomiting, dry mouth, decreased appetite, weight loss, abdominal pain), and cardiovascular systems (tachycardia, and palpitations).

Dermatologically, patients can complain of excessive sweating and ulceration of their digits.

Some patients may even develop blurry vision or decreased libido. While it rarely occurs, priapism is a medical emergency that requires immediate attention.[20] 

Patients are more prone to become easily agitated, irritable, or depressed and go through mood swings/lability.

While many common side effects can be relieved by adjusting the dosage or avoiding an afternoon or evening dose, some require treatment emergently to prevent complications.

It is important to note that there have been reported cases of sudden death in both children and adults with a pre-existing structural cardiac abnormality.[22] Stroke and myocardial infarction also have been observed in adults. Due to the risk of such fatal side effects, it is advisable to avoid methylphenidate in patients with a structural cardiac abnormality, cardiomyopathy, or arrhythmias.[23]

Drug Interactions: Methylphenidate can inhibit the metabolism of warfarin, phenytoin, tricyclic antidepressants, or SSRIs and can increase plasma concentration.

Contraindications

Patients must not use methylphenidate if they are currently on monoamine oxidase inhibitors (MAOIs). There should be a minimum of at least 14 days after discontinuation of MAOIs before methylphenidate can be considered a safe treatment option to begin due to the risk of hypertensive crisis.

Medical conditions that are not compatible with methylphenidate include glaucoma, severe hypertension, motor tics, Tourette syndrome, or a family history of Tourette syndrome.

If a patient is noticeably anxious, tense, or agitated, then seek alternative treatment options. However, it can be given cautiously in patients with a history of bipolar disorder or psychosis as long as clinicians are wary of mania or psychotic episodes induced by the medication.[12]

Any patient who develops a hypersensitive reaction to methylphenidate or an individual component of a formulation should have the medication immediately discontinued and switch to another pharmacologic agent.

Children under the age of six should not be prescribed this medication as there are limited studies to prove its safety or benefit, and it could cause learning impairments.

Monitoring

Since it has the potential risk of abuse, monitor patients for signs of dependence and or abuse while on therapy.

A complete blood count with differential should be obtained periodically for those on methylphenidate.

The main vitals to note at each visit are blood pressure and heart rate, especially in patients with underlying hypertension, heart failure, a recent MI, or ventricular arrhythmia, as slight elevations can occur with methylphenidate use. In addition, if a patient complains of cardiac symptoms, such as chest pain, that worsens with exertion or has a near-syncope episode, then a full cardiac workup should be performed.

In children, it is essential to evaluate their growth curve for a stable progression in height, and weight since methylphenidate has demonstrated growth suppression when used daily, long-term. The medication should either be readjusted or discontinued if children are not in a healthy percentile on their growth curve.[21]

Clinicians should screen for symptoms of depression, agitation, aggressiveness, new-onset or pre-existing psychosis or mania, and suicidality as these can be worsened when initially starting methylphenidate. Physicians should also monitor for signs of intravenous abuse as frank psychotic episodes can develop.

On physical exam, look for peripheral vasculitis (digital ulceration). 

Controversial evidence exists regarding the potential for methylphenidate to affect seizure threshold. If seizures develop while being treated with methylphenidate, the prescribing clinician should immediately stop the drug.[24][25]

In adults, patients should limit their alcohol use while taking methylphenidate as its stimulant action can mask the actual sedative effect caused by alcohol intoxication, possibly inducing severe respiratory depression.

Additionally, a patient who is concurrently on warfarin, phenytoin, tricyclic antidepressants, or SSRIs should have their drug levels monitored and adjust doses as needed to achieve a therapeutic effect.

Toxicity

The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the IR (immediate-release) formulation or 120 mg of the ER (extended-release) formulation can be considered toxic. If the overdosed quantity is unknown, look for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, IV fluids and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present.[20]

Enhancing Healthcare Team Outcomes

It is essential to gather a thorough history from the patient (or patient’s legal guardian) regarding their past medical history, current medications, and social history (obtain a developmental history if the patient is a child). An interprofessional healthcare team consisting of the patient’s primary care provider, psychiatrist, nurse practitioners, physician assistants, social workers, therapists, school teachers, and pharmacists should oversee the patient case. Communication between each member of the healthcare team is crucial as medication combined with non-pharmacologic treatment measures provide the most long-term success. Evaluation of side effects requires close monitoring at each visit. If the patient is a child, it is crucial to give patient’s legal guardian education regarding the medication and its side effects. This interprofessional approach will optimize therapeutic results while limiting adverse events. [Level 5]

Outcomes

Studies have shown that medication alone is not as effective as when methylphenidate is combined with non-pharmacologic treatment measures. Patients with ADHD managed on both medication, and non-pharmacologic treatments have been shown to have higher self-esteem and social functioning skills versus those untreated. Long-term beneficial effects have been shown in adults with ADHD who continue to take methylphenidate. Further long-term studies are still in progress.[26][27]

Review Questions

References

1.
Trenque T, Herlem E, Abou Taam M, Drame M. Methylphenidate off-label use and safety. Springerplus. 2014;3:286. [PMC free article: PMC4162523] [PubMed: 25279275]
2.
Thorpy MJ, Hiller G. The Medical and Economic Burden of Narcolepsy: Implications for Managed Care. Am Health Drug Benefits. 2017 Jul;10(5):233-241. [PMC free article: PMC5620503] [PubMed: 28975007]
3.
Theleritis C, Siarkos K, Katirtzoglou E, Politis A. Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities. J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49. [PubMed: 28248559]
4.
Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014 Jan-Feb;20(1):8-14. [PMC free article: PMC4510946] [PubMed: 24445757]
5.
Rojí R, Centeno C. The use of methylphenidate to relieve fatigue. Curr Opin Support Palliat Care. 2017 Dec;11(4):299-305. [PubMed: 28885263]
6.
Kolak A, Kamińska M, Wysokińska E, Surdyka D, Kieszko D, Pakieła M, Burdan F. The problem of fatigue in patients suffering from neoplastic disease. Contemp Oncol (Pozn). 2017;21(2):131-135. [PMC free article: PMC5611502] [PubMed: 28947882]
7.
Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015 Jun;172(6):561-9. [PMC free article: PMC4451432] [PubMed: 25677354]
8.
Ilieva IP, Hook CJ, Farah MJ. Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis. J Cogn Neurosci. 2015 Jun;27(6):1069-89. [PubMed: 25591060]
9.
Capp PK, Pearl PL, Conlon C. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Expert Rev Neurother. 2005 May;5(3):325-31. [PubMed: 15938665]
10.
Viggiano D, Vallone D, Sadile A. Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 2004;11(1-2):97-114. [PMC free article: PMC2565441] [PubMed: 15303308]
11.
Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ. The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Pharmazie. 2009 Feb;64(2):123-5. [PubMed: 19322953]
12.
Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, Hafizi S, Perez J, Fernandez-Egea E, Suckling J, Jones PB. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 19;370(1677):20140214. [PMC free article: PMC4528826] [PubMed: 26240429]
13.
Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P. Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2915-20. [PMC free article: PMC2650365] [PubMed: 19202072]
14.
Baker AS, Freeman MP. Management of Attention Deficit Hyperactivity Disorder During Pregnancy. Obstet Gynecol Clin North Am. 2018 Sep;45(3):495-509. [PubMed: 30092924]
15.
Damkier P. Methylphenidate and pregnancy. Br J Clin Pharmacol. 2014 Jun;77(6):1083. [PMC free article: PMC4093933] [PubMed: 24003978]
16.
Calvo-Ferrandiz E, Peraita-Adrados R. Narcolepsy with cataplexy and pregnancy: a case-control study. J Sleep Res. 2018 Apr;27(2):268-272. [PubMed: 28568319]
17.
Maurovich-Horvat E, Kemlink D, Högl B, Frauscher B, Ehrmann L, Geisler P, Ettenhuber K, Mayer G, Peraita-Adrados R, Calvo E, Lammers GJ, Van der Heide A, Ferini-Strambi L, Plazzi G, Poli F, Dauvilliers Y, Jennum P, Leonthin H, Mathis J, Wierzbicka A, Puertas FJ, Beitinger PA, Arnulf I, Riha RL, Tormášiová M, Slonková J, Nevšímalová S, Sonka K., European Narcolepsy Network. Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. J Sleep Res. 2013 Oct;22(5):496-512. [PubMed: 23560595]
18.
Bolea-Alamanac BM, Green A, Verma G, Maxwell P, Davies SJ. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol. 2014 Jan;77(1):96-101. [PMC free article: PMC3895350] [PubMed: 23593966]
19.
Ornoy A. Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation. Pharm Res. 2018 Feb 06;35(3):46. [PubMed: 29411149]
20.
Spiller HA, Hays HL, Aleguas A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs. 2013 Jul;27(7):531-43. [PubMed: 23757186]
21.
Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. Int Clin Psychopharmacol. 2016 Mar;31(2):93-9. [PMC free article: PMC4736299] [PubMed: 26544899]
22.
Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006 Apr 06;354(14):1445-8. [PubMed: 16549404]
23.
Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psychiatry. 2019 Oct;28(10):1283-1293. [PubMed: 30143889]
24.
Liu X, Carney PR, Bussing R, Segal R, Cottler LB, Winterstein AG. Stimulants Do Not Increase the Risk of Seizure-Related Hospitalizations in Children with Epilepsy. J Child Adolesc Psychopharmacol. 2018 Mar;28(2):111-116. [PMC free article: PMC5911707] [PubMed: 29028437]
25.
Ravi M, Ickowicz A. Epilepsy, Attention-Deficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence. J Can Acad Child Adolesc Psychiatry. 2016 Winter;25(1):50-8. [PMC free article: PMC4791106] [PubMed: 27047557]
26.
Harpin V, Mazzone L, Raynaud JP, Kahle J, Hodgkins P. Long-Term Outcomes of ADHD: A Systematic Review of Self-Esteem and Social Function. J Atten Disord. 2016 Apr;20(4):295-305. [PubMed: 23698916]
27.
Fredriksen M, Peleikis DE. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):23-31. [PubMed: 26404187]

Disclosure: Corinne Verghese declares no relevant financial relationships with ineligible companies.

Disclosure: Sara Abdijadid declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK482451PMID: 29494058

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...